Emergent BioSolutions Inc. 8-K

What Happened

• Emergent BioSolutions Inc. announced that on February 25, 2026 its Board appointed John D. Fowler, Jr. as a Class II director, effective March 1, 2026. His initial term expires at the company’s 2026 annual meeting of stockholders. Mr. Fowler is an independent director under NYSE standards and will serve on the Board’s Audit and Finance Committee.

Key Details

• Appointment date and effectiveness: appointed February 25, 2026; effective March 1, 2026; term expires at the 2026 annual meeting.
• Initial equity grant: restricted stock units valued at $270,000, vesting in three equal annual installments, subject to continued service.
• Director pay: annual cash retainer $70,000; additional $15,000 for Audit & Finance Committee membership; annual equity award valued at $270,000 (75% RSUs, 25% options), prorated for 2026.
• Governance notes: Mr. Fowler was not appointed pursuant to any outside arrangement and no related-party transactions requiring Item 404 disclosure were reported. He will sign the company’s standard indemnification agreement.

Why It Matters

• Board composition and independence affect corporate governance and oversight—adding an independent director with Audit Committee membership can influence financial oversight and risk management. The disclosed compensation and equity grants are material to shareholder dilution and executive/board pay trends. This 8-K informs investors about a near-term change to Emergent’s board and relevant director compensation.